Locations:
March 13, 2019/Cancer

Researchers Create Tool to Help Predict Survival for Patients with Advanced Stage Recurrent Ovarian Cancer

Time to recurrence most predictive

Ovarian-CA_650x450

Numerous past studies have shown that patients with ovarian cancer who respond to chemotherapy but then recur within six months generally live another 10 months. Survival for patients with ovarian cancer who respond to chemotherapy but recur later, however, is more variable. The advice given to such patients is usually just an average of how long all patients with recurrent ovarian cancer survive, 21 months.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Average survival times, however, do not provide much specific information to individual patients. Recently, a group of physicians from the NRG/Gynecologic Oncology Group analyzed clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian-peritoneal-tubal carcinoma. They then developed a nomogram to predict individual survival after recurrence.

“Patients want more specifics about their individual survival because it allows them to better plan for the future,” says Peter Rose, MD, who was first author on the study that was recently published in the journal Obstetrics and Gynecology.

Significant prognostic factors

The retrospective study included 4,739 patients, of which 84 percent had stage III and 16 percent had stage IV ovarian carcinoma. At a median follow-up of 88.8 months, the vast majority of patients (89.4 percent) had died. The median survival after recurrence was 21.4 months.

The investigators identified a number of significant prognostic factors, including: time to recurrence after initial chemotherapy, clear cell or mucinous histology, residual disease after primary surgery, performance status, stage IV disease and age. These factors are utilized to develop a nomogram to predict estimated survival for each patient.

Recurrence time

Dr. Rose says the group’s analysis shows that time to recurrence was by far the strongest variable for determining how long a patient would survive (accounting for 85 percent of the model). Residual disease, histology and performance status were the next most significant factors affecting survival after recurrence.

Advertisement

All of the patients in the study were treated with primary surgery followed by chemotherapy. More recently, however, oncologists have used neoadjuvant chemotherapy followed by surgery in patients with ovarian cancer. “It has become more popular because a lot of older people get ovarian cancer and they don’t do well with aggressive surgery,” Dr. Rose notes.

Dr. Rose suggests that the study’s cohort could be used as a control group for future studies. Researchers could compare survival outcomes of patients using new treatments to those of this group to determine whether the new drug prolongs a patient’s survival significantly.

Ovarian cancer

Nomogram for predicting median survival time after recurrence. To use, find the patient’s recurrence interval on the recurrence axis, then draw a straight line upward to the Points axis to determine how many points toward death the patient receives for her recurrence interval. Do this again for the other axes, each time drawing a straight line upward toward the Points axis. Sum the points received for each predictor and find the sum on the Total Points axis. Draw a straight line down to the median-survival axis to find the patient’s median survival time after recurrence of ovarian cancer.

Advertisement

Related Articles

Dr. Gerds
November 20, 2026/Cancer/Blood Cancers

Patient Case Study: Rusfertide Improves Quality of Life with Polycythemia Vera

Therapy eliminates the need for phlebotomies

Dr. Kevin Elias in the lab
November 18, 2026/Cancer

Spotting Ovarian Cancer Before it Starts

Inside Cleveland Clinic’s Quest for an Ovarian Cancer Screening Tool

Dr. Anwer and colleagues
November 12, 2026/Cancer/Blood Cancers

FDA Approval of Iberdomide Marks Historic Milestone in Multiple Myeloma

CELMoD therapy receives approval based primarily on measurable residual disease

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Ad